The inaugural Gene Therapy for Inherited Metabolic Disorders Summit will put the spotlight on the understanding of topics from the physiopathology of disease through to the nuances of dosing and delivery methods and designing a trial with endpoints and outcome measures that are meaningful both clinically and to patients.
Join 60+ industry leaders across the metabolic disorders space to overcome the specific delivery and drug development challenges to accelerate the development of more clinically efficacious, durable and safe gene therapies for metabolic disorders.
Don’t miss this opportunity to join pioneers from AstraZeneca, Amicus Therapeutics and Rocket Pharmaceuticals on this journey to revolutionize the treatment of inherited metabolic disorders.
To know more about Gene Therapy for Inherited Metabolic Disorders please click here.